

# Andrew St John

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1227661/publications.pdf>

Version: 2024-02-01

39  
papers

1,011  
citations

623734

14  
h-index

434195

31  
g-index

39  
all docs

39  
docs citations

39  
times ranked

1693  
citing authors

#	ARTICLE	IF	CITATIONS
1	Existing and Emerging Technologies for Point-of-Care Testing. <i>Clinical Biochemist Reviews</i> , 2014, 35, 155-67.	3.3	281
2	Point-of-care testing for patients with diabetes, hyperlipidaemia or coagulation disorders in the general practice setting: a systematic review. <i>Family Practice</i> , 2010, 27, 17-24.	1.9	120
3	Economic Evidence and Point-of-Care Testing. <i>Clinical Biochemist Reviews</i> , 2013, 34, 61-74.	3.3	78
4	The value of self-monitoring of blood glucose: a review of recent evidence. <i>Journal of Diabetes and Its Complications</i> , 2010, 24, 129-141.	2.3	65
5	Leveraging the real value of laboratory medicine with the value proposition. <i>Clinica Chimica Acta</i> , 2016, 462, 183-186.	1.1	50
6	How to manage warfarin therapy. <i>Australian Prescriber</i> , 2022, 38, 44-48.	1.0	46
7	Setting analytical performance specifications based on outcome studies – is it possible?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 841-8.	2.3	45
8	Nurse-based evaluation of point-of-care assays for glycated haemoglobin. <i>Clinica Chimica Acta</i> , 2006, 365, 257-263.	1.1	40
9	Biomarker development targeting unmet clinical needs. <i>Clinica Chimica Acta</i> , 2016, 460, 211-219.	1.1	39
10	Innovation in healthcare. The challenge for laboratory medicine. <i>Clinica Chimica Acta</i> , 2014, 427, 71-78.	1.1	37
11	High-sensitivity cardiac troponin I and risk of cardiovascular disease in an Australian population-based cohort. <i>Heart</i> , 2018, 104, 895-903.	2.9	32
12	Anatomy of a value proposition for laboratory medicine. <i>Clinica Chimica Acta</i> , 2014, 436, 104-111.	1.1	24
13	Setting clinical performance specifications to develop and evaluate biomarkers for clinical use. <i>Annals of Clinical Biochemistry</i> , 2019, 56, 527-535.	1.6	23
14	The role of failure modes and effects analysis in showing the benefits of automation in the blood bank. <i>Transfusion</i> , 2013, 53, 1077-1082.	1.6	16
15	The value proposition for point-of-care testing in healthcare: HbA1c for monitoring in diabetes management as an exemplar. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2019, 79, 298-304.	1.2	16
16	Developing a value proposition for high-sensitivity troponin testing. <i>Clinica Chimica Acta</i> , 2018, 477, 154-159.	1.1	12
17	High-sensitivity cardiac troponin I and risk of incident atrial fibrillation hospitalisation in an Australian community-based cohort: The Busselton health study. <i>Clinical Biochemistry</i> , 2018, 58, 20-25.	1.9	10
18	A value proposition for natriuretic peptide measurement in the assessment of patients with suspected acute heart failure. <i>Clinica Chimica Acta</i> , 2020, 500, 98-103.	1.1	9

#	ARTICLE	IF	CITATIONS
19	Testing at the Point-of-Care. Point of Care, 2011, 10, 182-185.	0.4	8
20	The Pursuit of Value in Laboratory Medicine – Progress and Challenges. , 2020, 41, 3-11.		8
21	Translational health economics: The key to accountable adoption of in vitro diagnostic technologies. Health Services Management Research, 2018, 31, 43-50.	1.7	7
22	Will COVID-19 be the coming of age for point-of-care testing?. BMJ Innovations, 2021, 7, 3-5.	1.7	6
23	Where Is the Value of Laboratory Medicine and How Do You Unlock It?. journal of applied laboratory medicine, The, 2020, 5, 1050-1060.	1.3	5
24	Implementing point-of-care CRP testing for better diagnosis of acute respiratory infections. British Journal of General Practice, 2022, 72, 87-88.	1.4	5
25	Internet support for –point-of-care testing in primary care. Australian Family Physician, 2015, 44, 10-1.	0.5	5
26	The Real Value of Laboratory Medicine. journal of applied laboratory medicine, The, 2016, 1, 101-103.	1.3	4
27	Economic Evaluations of Pathology Tests, 2010-2015: A Scoping Review. Value in Health, 2017, 20, 1210-1215.	0.3	4
28	Who Conducts Health Economic Evaluations of Laboratory Tests? A Scoping Review. journal of applied laboratory medicine, The, 2020, 5, 954-966.	1.3	4
29	The Role of Laboratory Medicine in Value-Based Healthcare. journal of applied laboratory medicine, The, 2020, 5, 1408-1410.	1.3	3
30	Translational health economics –delivering the return on investment for laboratory medicine. Journal of Laboratory and Precision Medicine, 0, 4, 30-30.	1.1	2
31	What is the return on investment for laboratory medicine? The antidote to silo budgeting in diagnostics. British Journal of Health Care Management, 2020, 26, 1-8.	0.2	2
32	Vitamin D testing: Impact of changes to testing guidelines on detection of patients at risk of vitamin D deficiency. Annals of Clinical Biochemistry, 2021, 58, 196-202.	1.6	2
33	EQA-derived metrics to assess overall instrument performance. Clinical Chemistry and Laboratory Medicine, 2016, 54, e177-9.	2.3	1
34	Health economic evaluations of medical tests: Translating laboratory information into value – A case study example. Annals of Clinical Biochemistry, 2021, , 000456322110138.	1.6	1
35	Implementation of medical tests in a Value-Based healthcare environment: A framework for delivering value. Clinica Chimica Acta, 2021, 521, 90-96.	1.1	1
36	Addressing Laboratory Workforce Issues in Australia. Clinical Chemistry, 2012, 58, 1722-1723.	3.2	0

#	ARTICLE	IF	CITATIONS
37	Determining value â€“ Do laboratory professionals need to learn more about the â€“dismal scienceâ€™?. Annals of Clinical Biochemistry, 2020, 57, 337-338.	1.6	0
38	Pointâ€“ofâ€“care testingâ€”Has it come of age?. Australian Journal of Rural Health, 2021, 29, 481-482.	1.5	0
39	How best to support point-of-care testing in the community?. Annals of Clinical Biochemistry, 2022, , 000456322210806.	1.6	0